Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A

Instrument sales account for roughly 65% of FY2024 revenue, with service and aftermarket contributing approximately 35%, providing only moderate forward visibility. Full-year 2025 organic revenue declined 3.7% when U.S. academic and government funding tightened, confirming the capital-equipment sensitivity to research funding cycles.

Bruker operates multiple instrument platforms spanning NMR/MRI (BioSpin), mass spectrometry (Daltonics), X-ray (AXS), and clinical diagnostics (ELITech), providing genuine cross-segment breadth. All platforms share dependence on life science and research spending, limiting true uncorrelated diversification.

Revenue is distributed across the Americas, Europe, and Asia-Pacific, with no single country representing more than roughly one-third of consolidated FY2024 revenue. The three-region structure has been maintained through multiple fiscal years, including periods of China weakness in 2025 and U.S. federal funding pressure.

Bruker's instrument manufacturing carries meaningful variable costs, and non-GAAP operating margin stood at approximately 15.7% in Q4 FY2025 as acquisition integration and softer volumes limited incremental leverage. The aftermarket services component provides higher-margin recurring revenue, but hardware intensity constrains the overall scalability profile.

Service contracts and consumables represent roughly 35% of FY2024 revenue and are mission-critical to researchers who depend on Bruker platforms for daily analytical work. The majority instrument-sale revenue is repeat-purchase within research institutions but is deferrable during funding constraints.